Hematology Faculty

Ravi Majeti, MD, PhD

Professor

Molecular characterization of human acute myeloid leukemia stem cells and their pathogenesis using bioinformatics, genomics, microfluidics, flow cytometry, and xenotransplantation assays in mice Development of novel therapeutic monoclonal antibodies directed against human acute myeloid leukemia stem cell surface antigens Investigation of normal human hematopoiesis and hematopoietic stem cells using similar techniques.

Go to lab

Steven E. Artandi, MD, PhD

Jerome and Daisy Low Gilbert Professor

• Understanding the early stages of cancer development
• Mechanisms in dyskeratosis congenita and other degenerative diseases
• Telomerase function inside human stem cells and cancer cells

Go to lab

Caroline Bérubé, MD

Clinical Associate Professor

Medical Director Outpatient Anticoagulation Clinic

General hematology

Specific interest in clinical thrombosis and hemostasis, management of anticoagulation, hemophilia, pregnancy-related hematologic conditions, immune thrombocytopenia, and anemia.

Ami Bhatt, MD, PhD

Assistant Professor

My laboratory uses molecular, micro- and computational biology techniques to dissect the role of the microbiota in hematological disorders.

We hope to target vulnerabilities in hematological disorders characterizing and modifying the human microbiota, thereby improving patient outcomes.

Go to lab

Linda M. Boxer, MD, PhD

Stanley McCormick Memorial Professor

Vice Dean, School of Medicine

Roni Brar, MD

Clinical Assistant Professor

Optimizing clinical evaluation for patients with benign and malignant hematologic conditions.

Novel clinical trials for acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and other hematologic malignancies.

Implementing personalized genomic medicine with high impact results into the clinic. 

Steven E. Coutré, MD

Professor

Clinical evaluation of platelet antagonists, hematopoietic growth factors and novel antithrombotics Development of clinical protocols for the treatment of hematologic malignancies including acute and chronic leukemias and multiple myeloma Director, Stanford Hematology Clinic

Tamara Dunn, MD

Clinical Assistant Professor

Program Director, Hematology Fellowship Program

Stanford Adolescent and Young Adult Cancer (SAYAC) Program

Lawrence Tim Goodnough, MD

Professor, Pathology & Medicine

• Oversees and supervises rotation of Hematology/ Oncology fellows in Transfusion Service
• Director, Transfusion Medicine Fellowship Program
• Associate Medical Director, Stanford Blood Center

View bio

Jason R. Gotlib, MD

Professor

Phase I/II trial evaluation of novel therapies for myelodysplastic syndromes, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic myeloproliferative disorders (MPDs, eg. polycythemia vera, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndromes, and systemic mastocytosis) Translational research collaborations to interrogate the molecular basis of CML and chronic MPDs
MPDs Associate Director, Stanford Myelodysplastic Syndromes Center Director, Hematology Division Tissue Bank Director, Med 8, Inpatient Hematology Service 

Peter L. Greenberg, MD

Professor, Emeritus (Active)  

As Director of the Stanford MDS Center, Dr Peter Greenberg has an active clinical practice focusing on evaluating and treating patients with myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and that is now evaluating the impact of molecular mutations on this risk-based prognostic system. He is Chair of the National Comprehensive Cancer Network (NCCN) Practice Guidelines Panel for MDS and is a member of the World Health Organization (WHO) Clinical Advisory Committee for Classification of  hematopoietic neoplasms: AML and myeloid neoplasms.

More research info

David Iberri, MD

Clinical Assistant Professor

Caring for patients with multiple myeloma, Waldenström macroglobulinemia, and related plasma-cell and lymphoid disorders.

Using novel biomarkers to personalize therapy and predict treatment response

Participating in clinical trials to advance the care of patients with a variety of hematologic malignancies including MDS, AML, and CLL.

Calvin J. Kuo, MD, PhD

Maureen Lyles D'Ambrogio Professor

• Organoid modeling of cancer
  
• Intestinal stem cell biology
  
• Blood-brain barrier vascular biology

Go to lab

Lawrence L.K. Leung, MD

Maureen Lyles D'Ambrogio Professor

Research:

1. Thrombin-activatable carboxypeptidase B2 in the crosstalk between coagulation, thrombosis, inflammation and innate immunity
2. Thrombin cleavage of osteopontin in cancer biology
3. Chemerin and insulin resistance
4. Epidemiology Center in Research and Information (ERIC) in support of genomics at Palo Alto VA

Michaela Liedtke, MD

Associate Professor

Director, Stanford Adolescent and Young Adult (AYA) Cancer Program

Design of clinical trials using new therapeutic strategies and experimental therapeutics for multiple myeloma, amyloidosis and acute lymphoblastic leukemia. Translational research collaborations to investigate the pathophysiology of amyloidosis. Development of a program addressing the unique needs of adolescents and young adults with cancer.

Amyloid Center

Stanford Adolescent and Young Adult Cancer (SAYAC) Program

Beth A. Martin, MD

Clinical Assistant Professor 

Clinical interests include the histiocytoses including HLH/MAS, autoimmune hematology including T-LGL, AIHA, and Castleman.  Educational interests include physical diagnosis, clinical decision-making and communication under desperate circumstances, and chemotherapy.  My research focuses on HLH.

Bruno Medeiros, MD

Affiliated Professor

My research interests focus on the experimental therapeutics of Acute Myeloid Leukemia (AML) with the ultimate goal of improving our understanding of the genomic abnormalities responsible for leukemogenesis and how these abnormalities can be exploited therapeutically. It also includes the development and incorporation of novel agents into the treatment regimens for young and older patients with AML and those with acute leukemia secondary to antecedent hematologic disorders.  

Beverly S. Mitchell, MD

George E. Becker Professor  

• Role of nucleotides in regulating nucleolar organization, function and cell proliferation
• Novel therapies for acute leukemia with correlative studies
• Function of a novel DNA repair protein with ubiquitin ligase activity

Elizabeth A. Price, MD, MPH

Assistant Professor

Clinical and laboratory characterization of unexplained anemia of aging Development of clinical protocol evaluating hematologic and functional response to interventions in unexplained anemia of aging

Stanley L. Schrier, MD

Professor, Emeritus (Active)

Red cell biology with emphasis on the pathophysiology and cell biology of the thalassemias, the causes of anemia in malaria, and the complex consequences of anemia in the aged

Amyloid Center

Tait Shanafelt, MD

Jeanie and Stew Ritchie Professor

Determining why people develop CLL and, its precursor condition, monoclonal B-cell lymphocytosis (MBL). 

Identifying molecular characteristics and prognostic tools that predict which CLL patients will experience a more aggressive disease course. 

• Identification and testing of new compounds for treating CLL. 

James L. Zehnder, MD

Professor

Clinical and laboratory investigation of thrombosis and bleeding disorders Molecular diagnostic testing for inherited thrombophilia and hematololymphoid malignancy